Top of this page
Skip navigation, go straight to the content

Our Science Pipeline

R&D pipeline

The UCB pipeline delivers:

-    a promising portfolio targeting severe diseases and addressing unmet medical needs
-    focus on neurological and immunological diseases
-    more convenient and effective treatments for patients and specialists.

UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

Small molecule drug / NCE

Small molecule drug / NCE

Antibody-based drug / NBE

Antibody-based drug / NBE



Neurology Indications Phase 1 Phase 2 Phase 3 Filed
padsevonil / UCB0942 (PPSI)epilepsy – highly drug resistant
phase 3 first quarter

UCB0599

Parkinson's disease
phase 1 half

UCB0107

Progressive Supranuclear Palsy (PSP)phase 1 half
Immunology Indications Phase 1 Phase 2 Phase 3 Filed
bimekizumab (IL17AF)psoriasisphase 3 half
 psoriatic arthritisphase 3 first quarter
 axial spondyloarthritis
phase 3 first quarter
dapirolizumab pegol**systemic lupus erythematosusphase 2
rozanolixizumab / UCB7665myasthenia gravisphase 2
 immune thrombocytopeniaphase 2
 chronic inflammatory demyelinating polyneuropathy (CIDP)phase 2 first quarter
UCB7858 / UCB0159auto-inflammatory diseasesphase 1 half
Bone Health Indications Phase 1 Phase 2 Phase 3 Filed

Evenity™
(romosozumab)*

osteoporosis in patients at high risk of fracture (Europe)
phase 4 half
*
**
In collaboration with Amgen - Launched in Japan / USA
In collaboration with Biogen